{
  "id": 5641989,
  "title": "Is Zoetis Stock Underperforming the S&P 500?",
  "url": "https://urgent.news/2026/09/03/is-zoetis-stock-underperforming-the-s-p-500",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-03T11:56:16.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/zoetis-stock-underperforming-p-500-115616664.html"
  },
  "original_language": "en",
  "account": "Zoetis Inc. (ZTS), a world-leading animal health company, is trading 50.9% below its 52-week high as of September 5, 2025. Despite its substantial market capitalization of $31.9 billion, ZTS has underperformed the S&P 500, which has seen a modest 12% year-to-date gain. The company's stock has plummeted 39.5% year-to-date and 50.2% over the past 52 weeks, making it significantly less profitable than its peers. Despite recent positive news, including a 3.9% increase following strong Q2 results, Zoetis continues to lag the broader market and its competitors, such as United Therapeutics Corporation (UTHR), which has outperformed ZTS by 21.5% over the past year. Analysts are cautiously optimistic about ZTS's future, with a moderate buy rating and a mean price target of $97.69, suggesting a 28.3% upside potential.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}